Shares of Catabasis Pharmaceuticls Inc. (NASDAQ:CATB) reached a new 52-week low during trading on Tuesday . The stock traded as low as $3.50 and last traded at $3.58, with a volume of 13,036 shares changing hands. The stock had previously closed at $3.79.

Several analysts recently commented on CATB shares. Citigroup Inc. dropped their price target on shares of Catabasis Pharmaceuticls from $21.00 to $16.00 and set a “buy” rating on the stock in a research report on Tuesday, March 22nd. Wedbush restated an “outperform” rating and set a $27.00 price target on shares of Catabasis Pharmaceuticls in a research report on Monday, March 28th. Oppenheimer Holdings Inc. reaffirmed a “buy” rating on shares of Catabasis Pharmaceuticls in a report on Saturday, May 14th. Cowen and Company reaffirmed a “buy” rating on shares of Catabasis Pharmaceuticls in a report on Saturday, May 14th. Finally, Zacks Investment Research raised shares of Catabasis Pharmaceuticls from a “hold” rating to a “buy” rating and set a $4.25 price objective on the stock in a report on Tuesday. Five investment analysts have rated the stock with a buy rating, Catabasis Pharmaceuticls currently has a consensus rating of “Buy” and an average price target of $19.05.

The firm’s market cap is $53.50 million. The firm has a 50-day moving average of $5.05 and a 200-day moving average of $5.55.

Catabasis Pharmaceuticls (NASDAQ:CATB) last announced its quarterly earnings data on Thursday, May 12th. The company reported ($0.61) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.03. On average, analysts anticipate that Catabasis Pharmaceuticls Inc. will post ($2.52) EPS for the current year.

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.